Vaccine Therapy in Treating Patients With Acute Myeloid Leukemia in Complete Remission
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT00963521|
Recruitment Status : Completed
First Posted : August 21, 2009
Last Update Posted : May 13, 2011
RATIONALE: Vaccines made from dendritic cells may help the body build an effective immune response to kill cancer cells.
PURPOSE: This phase I trial is studying the side effects of vaccine therapy and to see how well it works in treating patients with acute myeloid leukemia in complete remission.
|Condition or disease||Intervention/treatment||Phase|
|Leukemia||Biological: therapeutic autologous dendritic cells||Phase 1|
- Assess the tolerability of autologous dendritic cell vaccine in patients with acute myelogenous leukemia in complete remission.
- Evaluate the emergence of an immune response.
- Determine the relapse rate.
- Assess the occurrence of residual disease.
OUTLINE: Patients receive increasing doses of blastic cells transformed in vitro by autologous dendritic cells (1/3 subcutaneously and 2/3 IV) every 3 weeks for up to 5 doses.
|Study Type :||Interventional (Clinical Trial)|
|Estimated Enrollment :||10 participants|
|Official Title:||Pilot Study of Therapeutic Vaccination by Leukemic Blasts in Vitro Differentiated Dendritic Cells From Patients With Acute Myelogenous Leukemia in Complete Remission|
|Study Start Date :||June 2008|
|Actual Primary Completion Date :||May 2011|
- Adverse events at 6 months
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00963521
|Marseille Institute of Cancer - Institut J. Paoli and I. Calmettes|
|Marseille, France, 13273|
|OverallOfficial:||Christian Chabannon, MD, PhD||Institut Paoli-Calmettes|